FORMULATION AND CHARACTERIZATION OF DOLUTEGRAVIR MICROEMULSION TO IMPROVE ORAL BIOAVAILABILITY

The purpose of this research work is to Formulation and Characterization of Dolutegravir Microemulsion to Improve Oral Bioavailability for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. The present work is pre- formulation studies like organoleptic properties, solubility, compatibility studies by FTIR and calibration studies using UV spectroscopy. These studies aimed to Development of different formulations (DTR 1, 2, 3, 4) with various compositions. The studies which is involved in pre-formulation study of Microemulsion are Drug-excipient compatibility studies, Standard calibration curve of Dolutegravir and Preliminary Investigations like Screening of Oil for Microemulsion, Screening of Surfactant and Co-Surfactant and Construction of Phase Diagrams and finally by doing the studies like Thermodynamic Stability Studies, Type of Microemulsion, pH Determination, Rheological Characterization, Transmittance Test, Drug Content Estimation, In- vitro Drug Release Studies, Globule Size and Zeta Potential Measurement to confirmed the Characterization of Dolutegravir Microemulsion. The studies revealed that there is slight reduction in the drug content and % Transmittance after storage for 6months. From the data it was indicated that the optimized Dolutegravir Microemulsion can be stable up to 6 months. The study demonstrates that the developed Microemulsion DTR 4 formulation containing oleic acid (27%), Tween20 (28%), Ethanol (7%) and water (3%) is a transparent, less viscous system and stable system. Particle size and Zeta potential of optimized formulation were found tom be 54.30nm and - 5.61Mv. The stability studies confirmed that the optimized formulation can stable up to 6 months.